S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Neurocrine Biosciences Inc

NBIX XNAS
$152.25 +0.41 (+0.27%) ▲ 15-min delayed
Open
$150.00
High
$154.74
Low
$149.54
Volume
1.41M
Market Cap
$15.31B

About Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 2.0K Website →

Key Financials

Period Revenue Net Income EPS
Q1 2026 $814.50M $197.90M $1.97
FY 2025 $2.86B $478.60M $4.81
Q3 2025 $794.90M $209.50M $2.11
Q2 2025 $687.50M $107.50M $1.09

Related Market News

No specific coverage for NBIX yet. Check out our latest market news or earnings calendar.

Get NBIX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Neurocrine Biosciences Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.